Daunorubicin (Conventional)
Conventional Formulation
Cardiac, Myelosuppression; Extravasation Risk
- Avoid Extravasation: severe local tissue necrosis will occur.
- Intravenous infusion use only. Never administer via IM or SC route.
- Cardiotoxicity: Cumulative dose related. Potentially fatal CHF may occur months to years after completion of therapy.
- Myelosuppression: severe form may occur with therapeutic doses; this may lead to hemorrhage or infection
- Reduced dose in hepatic/renal dysfunction
- Cardiotoxicity cumulative dose related. Incidence of myocardial toxicity increases after a total cumulative dose > 400 to 550 mg/m2 in adults, >300 mg/m2 in children older than 2 yrs, and > 10 mg/kg in children less than 2 yrs.
- Experienced Physician in Equipped Facility
Monitoring data
- Careful hematological monitoring
- Evaluate EKG and systolic ejection fraction at baseline and before each course. A > 30% decrease in limb lead QRS associated with increased risk of cardiomyopathy.
- Cardiotoxicity cumulative dose related. Incidence of myocardial toxicity increases after a total cumulative dose > 400 to 550 mg/m2 in adults, >300 mg/m2 in children older than 2 yrs, and > 10 mg/kg in children less than 2 yrs.
- Increased risk associated with cardiac region radiation.
- Evaluate hepatic/renal function prior to initiation of therapy.
Package inserts
Additional information
Keywords: xx
Updated: October 2016